TAA5 CAR T
Alternative Names: Anti-FLT3 CAR-T Cell; FLT3 autologous chimeric antigen receptor T cells; FLT3 CAR-T cells; TAA-05; TAA05 cell injection; TAA5-CAR-TLatest Information Update: 11 Jul 2022
At a glance
- Originator PersonGen Biotherapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Acute myeloid leukaemia
Most Recent Events
- 14 Jun 2022 Phase-I clinical trials in Acute myeloid leukaemia (Second-line therapy or greater, Combination therapy) in China (Parenteral) (NCT05445011)
- 09 Jun 2022 Phase-I clinical trials in Acute myeloid leukaemia (Recurrent, Second-line therapy or greater) in China (IV) (NCT05432401)
- 20 Aug 2021 Phase-I/II clinical trials in Acute myeloid leukaemia (Second-line therapy or greater, In adolescents, In adults, In the elderly) in China (IV) (NCT05023707)